Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation

Author(s)

Almeida Junior, Luiz Domingues ; Valencise Quaglio, Ana Elisa ; Rodrigues de Almeida Costa, Celso Acacio ; Di Stasi, Luiz Claudio

• Document type: Journal article
• Source: WORLD JOURNAL OF GASTROENTEROLOGY; v. 23, n. 24, p. 4369-4380, JUN 28 2017.
• Web of Science Citations: 7

Abstract

AIM To investigate the effects of Ground Cherry (Physalis angulata L.) standardized supercritical CO2 extract in trinitrobenzenesulphonic acid (TNBS) model of rat intestinal inflammation. METHODS The animals were divided into groups that received vehicle or P. angulata extract (PACO(2)) orally at the doses 25, 50 and 100 mg/kg daily by 5 d before TNBS damage. Protective effects of PACO(2) were assessed by macroscopic analysis, biochemical determinations of the levels of myeloperoxidase (MPO), alkaline phosphatase (ALP), glutathione and cytokines (such as INF-gamma, IL1 beta, IL-6, IL-10 and TNF-alpha), gene expression evaluation (including Hsp70, heparanase, NF-kappa B, mitogenactivated protein kinases (Mapk) 1, 3, 6 and 9, and the mucins genes Muc 1, 2, 3 and 4) and histopathological studies using optical, and electronic (transmission and scanning) microscopy. RESULTS PACO(2) extract promoted a significant reduction in MPO and ALP activities, reducing oxidative stress and neutrophil infiltration. These effects were accompanied by significant reduction of colonic levels of IFN-gamma. and IL-6 and down-regulation of heparanase, Hsp70, Mapk3, Mapk9, Muc1 and Muc2 genes expression when compared with TNBS-control animals. In addition, protective effects were also evidenced by reduced neutrophil infiltration, recovery of cell architecture and replacement of mucin by histopathological and ultrastructural analysis. CONCLUSION Physalis angulata supercritical CO2 extract is an intestinal anti-inflammatory product that modulates oxidative stress, immune response and expression of inflammatory mediators, with potentially utility for treating inflammatory bowel disease. (AU)

• FAPESP's process: 11/50512-2 - Inflammatory bowel disease (IBD): new molecular markers and intestinal anti-inflammatory activity of drugs and plant products
• Grantee: Luiz Claudio Di Stasi
• Support Opportunities: Regular Research Grants
• FAPESP's process: 15/15267-8 - Inflammatory bowel disease (IBD): novel approaches for diagnosis and gut microbiota modulation in ulcerative colitis patients
• Grantee: Luiz Claudio Di Stasi
• Support Opportunities: Research Projects - Thematic Grants